![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Successful Retreatment With Sofosbuvir-containing Regimens for HCV Genotype 2 or 3 Infected Patients who Failed Prior Sofosbuvir Plus Ribavirin Therapy
|
|
|
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Rafael Esteban1, Lisa Nyberg2, Jay Lalezari3, Liyun Ni4, Brian Doehle4, Bittoo
Kanwar4, Diana Brainard4, GM Subramanian4, William T. Symonds4, John G.
McHutchison4, Maribel Rodriquez-Torres5, Stefan Zeuzem6
1Vall d'Hebron Hospital, Barcelona, Spain; 2Kaiser Permanente, San Diego, CA, USA; 3Quest Clinical Research, San Francisco, CA, USA; 4Gilead Sciences, Inc., Foster City, CA, USA; 5Fundacion de Investigacion, San Juan, Puerto Rico; 6JW Goethe University Hospital, Frankfurt, Germany
![EASL1.gif](../images/041414/041414-12/EASL1.gif)
![EASL2.gif](../images/041414/041414-12/EASL2.gif)
![EASL3.gif](../images/041414/041414-12/EASL3.gif)
![EASL4.gif](../images/041414/041414-12/EASL4.gif)
![EASL5.gif](../images/041414/041414-12/EASL5.gif)
![EASL6.gif](../images/041414/041414-12/EASL6.gif)
![EASL7.gif](../images/041414/041414-12/EASL7.gif)
![EASL8.gif](../images/041414/041414-12/EASL8.gif)
![EASL9.gif](../images/041414/041414-12/EASL9.gif)
![EASL10.gif](../images/041414/041414-12/EASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|